Eli Lilly Aktie
WKN: 858560 / ISIN: US5324571083
|
19.03.2026 12:35:11
|
Lilly Reports Positive Data From Phase 3 TRANSCEND-T2D-1 Study Of Retatrutide
(RTTNews) - Eli Lilly and Company (LLY) on Thursday reported positive topline results from its Phase 3 TRANSCEND-T2D-1 study of retatrutide in adults with type 2 diabetes.
The trial met its primary and all key secondary endpoints, showing superior A1C reduction and weight loss at 40 weeks compared to placebo. Participants treated with retatrutide achieved average A1C reductions of up to 2%, while also losing up to 36.6 pounds (16.8%) on average, with weight loss continuing through the treatment period.
Lilly shares had closed at $918.05, down 1.32%.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Eli Lilly
Analysen zu Eli Lilly
| 04.02.26 | Eli Lilly Buy | Goldman Sachs Group Inc. | |
| 20.12.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
| 31.10.24 | Eli Lilly Buy | Jefferies & Company Inc. |
Aktien in diesem Artikel
| Eli Lilly | 755,10 | -3,61% |
|